X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5441) 5441
Newspaper Article (51) 51
Newsletter (47) 47
Magazine Article (32) 32
Transcript (10) 10
Book Chapter (4) 4
Book Review (4) 4
Dissertation (2) 2
Paper (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
Reference (1) 1
Report (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4613) 4613
interferon-beta - therapeutic use (3082) 3082
female (2294) 2294
multiple sclerosis (2241) 2241
male (2051) 2051
adult (1864) 1864
multiple sclerosis - drug therapy (1622) 1622
clinical neurology (1472) 1472
middle aged (1374) 1374
interferon-beta (1310) 1310
interferon beta-1a (1062) 1062
animals (1039) 1039
interferon beta (978) 978
neurosciences (953) 953
interferon (950) 950
treatment outcome (942) 942
multiple sclerosis, relapsing-remitting - drug therapy (870) 870
adjuvants, immunologic - therapeutic use (817) 817
immunology (787) 787
interferon beta-1b (767) 767
glatiramer acetate (725) 725
immunologic factors - therapeutic use (678) 678
biological response modifiers (628) 628
mice (620) 620
neurology (616) 616
magnetic resonance imaging (606) 606
therapy (570) 570
double-blind (569) 569
interferon-beta - administration & dosage (567) 567
multiple sclerosis - immunology (564) 564
interferon-beta - adverse effects (521) 521
care and treatment (494) 494
disease progression (492) 492
pharmacology & pharmacy (476) 476
research (451) 451
immunosuppressive agents - therapeutic use (450) 450
adolescent (449) 449
interferon-beta - pharmacology (441) 441
interferon-beta - immunology (421) 421
time factors (410) 410
aged (409) 409
multiple sclerosis - therapy (404) 404
peptides - therapeutic use (404) 404
health aspects (401) 401
drug therapy (380) 380
expression (367) 367
disability (354) 354
multiple-sclerosis (350) 350
young adult (339) 339
recurrence (336) 336
follow-up studies (334) 334
disability evaluation (320) 320
inflammation (311) 311
cytokines (303) 303
interferon-beta - metabolism (301) 301
neutralizing antibodies (300) 300
oncology (299) 299
placebo-controlled trial (299) 299
multiple sclerosis - diagnosis (298) 298
medicine & public health (296) 296
cell biology (292) 292
ifn-beta (284) 284
disease (283) 283
analysis (282) 282
multiple sclerosis - pathology (277) 277
medicine, general & internal (275) 275
natalizumab (273) 273
multicenter (272) 272
antiviral agents - therapeutic use (264) 264
multiple sclerosis - physiopathology (262) 262
brain - pathology (261) 261
clinical trials as topic (261) 261
interferon-beta - genetics (261) 261
biochemistry & molecular biology (260) 260
gene expression (259) 259
research article (257) 257
experimental autoimmune encephalomyelitis (256) 256
medicine, research & experimental (253) 253
retrospective studies (248) 248
multiple sclerosis, relapsing-remitting - immunology (239) 239
cells, cultured (234) 234
proteins (229) 229
medicine (227) 227
immunotherapy (226) 226
interferon-β (226) 226
interferon-alpha - therapeutic use (222) 222
psychiatry (222) 222
t-cells (222) 222
mri (217) 217
drug therapy, combination (215) 215
central-nervous-system (213) 213
prospective studies (213) 213
cells (212) 212
mice, inbred c57bl (212) 212
recombinant proteins - therapeutic use (211) 211
dose-response relationship, drug (208) 208
activation (204) 204
dendritic cells (203) 203
cancer (200) 200
clinical trials (200) 200
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5251) 5251
Japanese (83) 83
German (79) 79
Spanish (75) 75
Russian (64) 64
French (52) 52
Italian (24) 24
Polish (24) 24
Portuguese (22) 22
Chinese (15) 15
Hungarian (14) 14
Dutch (10) 10
Danish (9) 9
Finnish (6) 6
Swedish (5) 5
Croatian (4) 4
Norwegian (3) 3
Czech (1) 1
Hebrew (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA : the journal of the American Medical Association, ISSN 0098-7484, 01/2019, Volume 321, Issue 2, pp. 175 - 187
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 01/2017, Volume 2017, Issue 1, pp. CD010369 - CD010369
Background Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic progressive or relapsing and remitting disease that usually causes... 
Immunoglobulin treatment | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Chronic inflammatory demyelinating polyradiculopathy | Dexamethasone | Immunosuppressive Agents | Chronic inflammatory demyelinating polyradiculoneuropathy | Adrenal Cortex Hormones | Interferon beta‐1a | Prednisone | Immunosuppressive and immunomodulatory treatment | Plasma Exchange | Methylprednisolone | Peripheral neuropathy | Randomized Controlled Trials as Topic | Plasma exchange treatment | Neurology | Review Literature as Topic | Azathioprine | Methotrexate | Medicine General & Introductory Medical Sciences | Immunoglobulins, Intravenous | Corticosteroid treatment | MEDICINE, GENERAL & INTERNAL | PLASMA-EXCHANGE | NEUROMUSCULAR DISORDERS | MULTIPLE-SCLEROSIS | DOUBLE-BLIND | INTRAVENOUS IMMUNOGLOBULIN TREATMENT | INTEROBSERVER AGREEMENT | RANDOMIZED CONTROLLED-TRIAL | QUALITY-OF-LIFE | METHODOLOGICAL QUALITY | TECHNOLOGY-ASSESSMENT SUBCOMMITTEE | Azathioprine - therapeutic use | Interferon beta-1a - therapeutic use | Methylprednisolone - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Methotrexate - therapeutic use | Adrenal Cortex Hormones - therapeutic use | Dexamethasone - therapeutic use | Immunoglobulins, Intravenous - therapeutic use | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - therapy | Prednisone - therapeutic use | Index Medicus
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2015, Volume 37, Issue 4, pp. 691 - 715
Abstract Purpose Interferon injectables and glatiramer acetate have served as the primary disease-modifying treatments for multiple sclerosis (MS) since their... 
Internal Medicine | Medical Education | cost | disease-modifying treatments | multiple sclerosis | new drugs | pharmacotherapy | cost disease-modifying treatments multiple sclerosis new drugs pharmacotherapy | PEGYLATED INTERFERON BETA-1A | COST-EFFECTIVENESS | ORAL FINGOLIMOD FTY720 | PLACEBO-CONTROLLED PHASE-3 | INTRAMUSCULAR INTERFERON | CLINICAL-EFFICACY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | GLATIRAMER ACETATE | BG-12 DIMETHYL FUMARATE | QUALITY-OF-LIFE | United States | Humans | Immunosuppressive Agents - therapeutic use | Drug Approval | Polyethylene Glycols - economics | Polyethylene Glycols - therapeutic use | Interferon-beta - therapeutic use | Antibodies, Monoclonal, Humanized - economics | Dimethyl Fumarate - economics | Drug Costs - statistics & numerical data | Immunosuppressive Agents - economics | Fingolimod Hydrochloride - therapeutic use | Toluidines - economics | United States Food and Drug Administration | Fingolimod Hydrochloride - economics | Toluidines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Multiple Sclerosis - economics | Alemtuzumab | Interferon-beta - economics | Crotonates - therapeutic use | Crotonates - economics | Dimethyl Fumarate - therapeutic use | Glatiramer Acetate - therapeutic use | Glatiramer Acetate - economics | Multiple Sclerosis - drug therapy | Multiple sclerosis | Care and treatment | Biological response modifiers | Drug approval | Interferon | FDA approval | Drug therapy
Journal Article
Lancet neurology, ISSN 1474-4422, 2012, Volume 11, Issue 5, pp. 420 - 428
Journal Article
Nature communications, ISSN 2041-1723, 2020, Volume 11, Issue 1, pp. 222 - 14
Journal Article